drugset / Trial / NCT01125761

Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

NCT01125761

Phase 3 Withdrawn Azidus Brasil
RandomizedParallel-groupSingle-blindTreatment

Summary

Considering the pathogenesis of several allergic skin diseases to be investigated in this study as well as the pharmacodynamic mechanisms of the association of dexamethasone and clemastine fumarate, it is believed that the components of topical medication may act synergistically in the reduction of signs and symptoms of the diseases in question. Therefore it is expected that the association promotes results significantly superior to dexamethasone alone.

Timeline

Start
2010-11
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Clemastine Small molecule 1 mg Topical
Subject Dexamethasone Small molecule 0.5 mg Topical

Indications